
    
      Patients receive weekly Ixabepilone 32 mg/m2 (D1) and a 4-level of oral Lapatinib 500-1250 mg
      once daily continuously. The recommended duration of treatment for each patient 21 days a
      cycle of total 6 cycles or until disease progression, or unacceptable toxicity or patient's
      refusal occurred.
    
  